Rivaroxaban in Left Ventricular Thrombus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 261 participants.

Also called NCT04970576

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 261 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04970576
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04970576. Randomized; single masking; primary purpose treatment. Start 2021-06-25 (actual); primary completion 2024-05-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban in Left Ventricular Thrombus
Condition
Acute Coronary Syndrome
Condition
Left Ventricular Thrombus
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Warfarin
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan (class: other)

Record details

Record id
cardio:ct-nct04970576
Content hash
c92f96fd8e9f8bb9ffd20ecd36cff112b7575f6ee7493548c61b6e29091fd35a